empty
 
 
bg
Търсене
Подкрепа
Незабавно отваряне на акаунт
Платформа за търговия
Депозит / Теглене
Търсене
За начинаещи За търговци За партньори Вземете си почивка За ИнстаФорекс
bg
#ACB Обратно към списъка с инструменти #AMGN

Конвентор на валута

Alnylam Pharmaceuticals Inc.
319.8 USD
11 Mar 2026 22:59
Ценова промяна (% chg)
$0
(0%)
Предишно затваряне
Предишно затваряне

Затваряща цена, предишен ден.
$323.26
Отваряне
Отваряне

Цена на отваряне.
$322.79
Дневен връх
Дневен връх

Най-високата цена през последния търговски ден.
$323.26
Дневно дъно
Дневно дъно

Най-ниската цена през последния ден за търговия
$316.98
52-седмичен връх
52-седмичен връх

Връх на ценовия диапазон за последните 52 седмици
$324.42
52-седмично дъно
52-седмично дъно

Дъно на ценовия диапазон за последните 52 седмици
$314.5
Свалете архива
Buy
319.8
Sell
319.8
Open the chart in full screen view
Buy
319.8
Sell
319.8
Свалете архива
Open the chart in full screen view

Alnylam Pharmaceuticals Inc. About company

Alnylam Pharmaceuticals Inc. is an American biopharmaceutical company, founded in 2002. The firm is mainly involved in the research and development of drugs for treating genetic disorders.

In 2016, Alnylam Pharmaceuticals Inc. was added to the Forbes list of the world’s 100 most innovative growth companies.

This year, the market capitalization of Alnylam Pharmaceuticals Inc. totals $17.65 billion. In 2021, it raised revenue of $844.29 million. In the first six months of 2022, the company earned as much as $224.82 million.

Alnylam Pharmaceuticals Inc.’s shares and factors shaping their value

The company has been listed on the NASDAQ exchange since 2004 under the ALNY ticker. Its share value currently totals $200-205. Over the past 12 months, ALNY has fluctuated in the range of $117 to $236.

When trading the firm’s stock, you should pay attention to the following factors:

  • The company has a heavy dependence on the state of the healthcare sector as a whole. Thus, new COVID outbreaks have a negative influence on its revenue growth;
  • The company occasionally introduces new drugs to the market, conducting clinical and laboratory trials and publishing the results beforehand;
  • Constantly growing revenues are the firm’s advantage;
  • Enough own funds to finance projects without the need to additionally issue securities.

Не можете да говорите точно сега?
Задайте въпроса си в чат.